Status:
COMPLETED
Chronic Ibrutinib Therapy Effect on Left Atrial Function
Lead Sponsor:
University Hospital Sestre Milosrdnice
Conditions:
Atrium; Beat
Echocardiography
Eligibility:
All Genders
18+ years
Brief Summary
Ibrutinib is an irreversible Bruton tyrosine-kinase inhibitor. In prospective studies, the ibrutinib efficacy in the treatment of various B-cell malignancies was established. Different ibrutinib side-...
Eligibility Criteria
Inclusion
- patients with haemato-oncologic diseases (including chronic lymphocytic leukemia, Mantle-cell lymphoma, Waldenstrom macroglobulinaemia, etc.)
- patients prescribed with chronic ibrutinib therapy
- patients who are able to understand and sign informed consent
Exclusion
- patients with haemato-oncologic diseases who were prescribed with concomitant chemotherapy which can impact left atrial function
- patients \< 18 years old
- patients with known or at initial echocardiography established dilated cardiomyopathy with left ventricular ejection fraction \< 35%
- patients with permanent atrial fibrillation and dilated left atrium or dilated both atriums
- patients implanted with cardiac implantable electronic devices
- patients who underwent cardiac surgery
- patients with congenital heart diseases (surgically corrected or not)
- patients with severe valvular pathology
- patients with terminal renal disease
- patients with chronic obstructive pulmonary disease - GOLD grade 4
- patients with life expectancy \< 12 months
- patients not willing to undergo clinical follow-up or sign informed consent
- patients recruited in another clinical study
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 4 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03751410
Start Date
December 1 2018
End Date
March 4 2023
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sestre milosrdnice University Hospital
Zagreb, Croatia, 10000